联合王国禁止为误导性癌症和健康索赔提供前列腺补充广告和测试广告。 UK bans prostate supplement and test ads for misleading cancer and health claims.

英国广告标准管理局禁止4个前列腺补充品和2个家庭测试包的广告,因为这些广告对治疗或诊断前列腺状况提出了误导性的说法。 The UK’s Advertising Standards Authority has banned ads for four prostate supplements and two home testing kits for making misleading claims about treating or diagnosing prostate conditions. 这些补充材料虚假地暗示,它们可以解决诸如扩大的前列腺或尿道问题等问题,尽管没有得到授权的药品。 The supplements falsely implied they could address issues like enlarged prostate or urinary problems, despite not being authorized medicines. 测试包错误地指出,它们可以检测或排除前列腺癌,尽管光是PSA测试无法证实癌症。 The testing kits wrongly suggested they could detect or rule out prostate cancer, though PSA tests alone cannot confirm cancer. 审计署发现,即使提出免责声明,申诉也具有误导性,并警告说,他们可能拖延适当的医疗服务。 The ASA found the claims misleading, even with disclaimers, and warned they could delay proper medical care. AI-动力监测有助于在更广泛的审查中确定广告,而MAHRA支持这一行动,强调家用测试不是确定性的,不应取代专业医疗建议。 AI-powered monitoring helped identify the ads during a broader review, and the MHRA supported the action, stressing that at-home tests are not definitive and should not replace professional medical advice. 敦促消费者向保健提供者咨询。 Consumers are urged to consult healthcare providers.